CN110101817A - 一种治疗心血管疾病的中药组合物及其制备方法 - Google Patents
一种治疗心血管疾病的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN110101817A CN110101817A CN201910419371.6A CN201910419371A CN110101817A CN 110101817 A CN110101817 A CN 110101817A CN 201910419371 A CN201910419371 A CN 201910419371A CN 110101817 A CN110101817 A CN 110101817A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- ginseng
- cardiovascular disease
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 19
- 239000002775 capsule Substances 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 241000208340 Araliaceae Species 0.000 claims description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 26
- 235000008434 ginseng Nutrition 0.000 claims description 26
- 239000000341 volatile oil Substances 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims description 15
- 235000019441 ethanol Nutrition 0.000 claims description 15
- 239000001116 FEMA 4028 Substances 0.000 claims description 13
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 13
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 13
- 229960004853 betadex Drugs 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001256 steam distillation Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- 230000036284 oxygen consumption Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 9
- 239000006187 pill Substances 0.000 description 8
- 229960001597 nifedipine Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000009524 danshen dripping Substances 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000005304 joining Methods 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019890 Amylum Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药组合物及其制备方法,特别是涉及治疗心血管疾病的中药组合物及其制备方法。本发明的目的是针对现有技术的不足之处,提供一种可以标本兼治,扩冠、镇静、降低心肌耗氧量,提高应激能力,更加显著的治疗冠心病、心绞痛的药物。同时,本发明提供该药物的临床应用制剂。
Description
技术领域
本发明涉及一种中药组合物及其制备方法,特别是涉及治疗心血管疾病的中药组合物及其制备方法。
背景技术
祖国传统医学将心血管疾病中的冠心病、心绞痛归属于“胸痹”、“真心痛”的范畴,认为其发病原因主要有年老体衰,元气不足,推动血液运行乏力,血行迟缓;七情内伤:即喜、怒、忧、思、悲、恐、惊等使精神受到创伤,情绪波动剧烈,使之气郁不畅,气滞血瘀,心脉闭阻,不通则痛;饮食不节,暴饮暴食,饱餐过度,尤其是进食高脂食物无节制,造成脾胃失调,湿困脾胃,而成痰浊,痰浊阻滞脉道,瘀阻心脉,造成心肌缺血而发生心绞痛。
在现代医学临床中,心血管疾病是发病率最高的疾病之一,严重影响人类的健康。临床常见胸闷、气短、心悸等,或伴有倦怠乏力,懒言;或时欲太息,遇情怀不畅则诱发或加剧;或痰黄稠厚,心烦、口干,大便干或秘。可因一时性或持续性心肌缺血缺氧出现心绞痛。重者可因冠状动脉突然闭塞导致心肌缺血、坏死、形成心肌梗塞。因此,在治疗中既要消除原发致病因素(劳累、情绪激动等)又需对症治疗(止痛、通便等)。
该中药组合物可采用下列制备方法制备:取人参加入乙醇,回流提取,同法提取两次,合并回流提取液,减压回收乙醇至无醇味,放置备用;川芎、黄精加水,用蒸气蒸馏法提取挥发油,用β-环糊精包合得挥发油包合物。合并人参提取液加入挥发油包合物和辅料,采用常规工艺,制成胶囊、颗粒剂、片剂或口服液。
专利保护组方、剂量和现代制药技术的参数。
发明内容
本发明的目的是针对现有技术的不足之处,提供一种可以标本兼治,扩冠、镇静、降低心肌耗氧量,提高应激能力,更加显著的治疗冠心病、心绞痛的药物。同时,本发明提供该药物的临床应用制剂。
技术方案的具体内容如下:
本发明提供了一种治疗心血管疾病的中药组合物,其特征在于,所述中药组合物包括以下重量份的原材料:人参,6-12g;黄精,10-30;川芎,9-15g;郁金,9-15g份;β-环糊精,5-20g;辅料,3-9g。
在一些实施方案中,所述中药组合物包括以下重量份的原材料:人参,6-9g;(缩小)黄精,10-18g份;(缩小)川芎,9-12g;(缩小)郁金,9-12g;(缩小)β-环糊精,5-10g;(缩小)辅料,3-6g。(缩小)
在一些实施方案中,所述中药组合物包括以下重量份的原材料:人参6g;(最优)黄精,15g;(最优)川芎,12g;(最优)郁金,12g;(最优)β-环糊精,5g;(最优)辅料,3g。(最优)
在一些实施方案中,所述辅料包括:可压性淀粉。
在一些实施方案中,该制剂由中药组合物和药学上可接受的载体或赋形剂组成。
具体的,在一些实施方案中,所述内用剂型为胶囊、颗粒剂、片剂或口服液剂。
另外,本发明还提供了一种制备所述的治疗心血管疾病的中药组合物的方法,所述中药组合物胶囊的制备方法包括以下步骤:1)取人参、黄精、川芎,将人参加入6倍量75%乙醇,回流提取3次,每次1.5小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;2)郁金、川芎加14倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,调整相对密度,采用常规工艺,制成胶囊。
一种制备权利要求1-4任一所述的治疗心血管疾病的中药组合物的方法,其特征在于,所述中药组合物颗粒的制备方法包括以下步骤:
1)取人参、黄精、川芎将人参加入4倍量75%乙醇,回流提取3次,每次1小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;
2)黄精、川芎加10倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;
3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,一步制粒,40℃-60℃低温干燥,制成颗粒剂。
通过上述提供的方案,在冠心病的临床治疗中可以实现标本兼治,扩冠、镇静、降低心肌耗氧量,提高应激能力,更加显著的治疗冠心病、心绞痛。
具体实施方式
实施例1
本实施例公开了本发明提供了一种治疗心血管疾病的中药组合物,所述中药组合物包括以下重量份的原材料:人参6g;黄精,15g;川芎,12g;郁金,12g;β-环糊精,5g;辅料,3g。
在一些实施例中,所述中药组合物包括以下重量份的原材料:人参,6-9g;(缩小)黄精,10-18g份;川芎,9-12g;郁金,9-12g;β-环糊精,5-10g;辅料,3-6g。
在一些实施例中,所述中药组合物包括以下重量份的原材料:人参6g;黄精,15g;川芎,12g;郁金,12g;β-环糊精,5g;辅料,3g。
实施例2
根据上述实施例1,本实施例还提供了一种制备所述的治疗心血管疾病的中药组合物的方法,所述中药组合物胶囊的制备方法包括以下步骤:1)取人参、黄精、川芎,将人参加入6倍量75%乙醇,回流提取3次,每次1.5小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;2)郁金、川芎加14倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,调整相对密度,采用常规工艺,制成胶囊。
实施例3
一种制备权利要求1-4任一所述的治疗心血管疾病的中药组合物的方法,其特征在于,所述中药组合物颗粒的制备方法包括以下步骤:1)取人参、黄精、川芎将人参加入4倍量75%乙醇,回流提取3次,每次1小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;2)黄精、川芎加10倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,一步制粒,40℃-60℃低温干燥,制成颗粒剂。
其中,上述各实施例中的辅料为可压性淀粉。
为说明上述实施例1-3的效果,下面通过实施例制备的胶囊进行试验,以验证本发明的治疗效果。
实验例1
1实验目的:观察本发明胶囊(参精胶囊)对心肌缺血的改善作用
2材料与方法
2.1材料
2.1.1动物:健康雄性Wistar大鼠,体重210—230g,由北京维通利华实验动物技术有限公司提供,实验动物合格证号:SCXK(京)2002-0006。
2.1.2药品与试剂:参精胶囊,由本研究所制剂研究室李慧博士提供,批号:20040615。每克相当于100克生药。复方丹参滴丸,北京天士力制药股份有限公司,批号:20060612;硝苯地平片,北京太洋药业有限公司,批号:041003。N-BT上海前进化学试剂厂,Q/BKJS 2-92。
2.1.3仪器:小动物呼吸机(江西省特力麻醉呼吸公司生产TRK-200型);多导生理记录仪,BIOPAC150型,美国生产;气浴摇床,美国Thermo forma公司生产。
2.2方法
2.2.1动物分组,健康Wistar大鼠84只,随机分为6组,1)假手术组:仅开胸、穿线不结扎。2)模型组及各给药组:按照模型制作方法进行造模。硝苯地平组,灌服硝苯地平(3mg/kg/d);复方丹参滴丸组,灌服复方丹参滴丸(83mg/kg/d);参精胶囊低剂量组,灌服参精胶囊(25mg/kg/d);参精胶囊高剂量组,灌服参精胶囊(50mg/kg/d)。各组动物按上述剂量连续灌胃给药7d,假手术组与模型组均给予等容量生理盐水(10ml/kg/d)。
2.2.2模型制备及标本采集,第8天在给药1h后,用3%戊巴比妥钠腹腔麻醉大鼠。然后仰卧位固定于手术台上,分离气管,插入气管插管,连接小动物呼吸机,室内空气通气,频率90次/min,潮气量3-4mL。向大鼠四肢皮下插入针形电极,描记Ⅰ、Ⅱ、Ⅲ、aVF、aVL、aVR导联心电图。胸部去毛、消毒,沿左锁骨中线纵行切开皮肤,在第4肋间钝性分离肌层,打开胸腔,剪开心包,结扎左冠状动脉造成心肌缺血,迅速缝合胸壁,缝合关闭气管。其间监测心电图变化,以判断心肌缺血模型中否成功,未造成缺血者则弃之不用。24h后将大鼠心脏剪下,用生理盐水冲去血污,-20℃冰箱内冷冻15min,做心脏切片。
2.2.3梗死区心肌染色,从心尖向心底方向将心脏均匀切为8片,将其置于0.1%的NBT溶液中,37℃气浴摇床摇动10min,用吸水纸吸干表面水分,按顺序摆放,拍照;分别切取梗死区与非梗死区并称量,计算心梗指数。心梗指数=梗死区湿质量/全心湿质量。
2.2.4统计处理,所有数据用平均数±标准差表示,采用T检验方法统计组间差异。
3结果
3.1参精胶囊对急性心肌缺血大鼠心梗指数的影响,见表1。
表1参精胶囊对急性心肌缺血大鼠梗死重量的影响
注:模型组与假手术组相比*P<0.01注:治疗组与模型组相比**P<0.01,参精胶囊高、低剂量组与硝苯地平、丹参滴丸组比较△△P<0.01,参精胶囊高剂量组与低剂量组比▼P<0.05。
4数据分析
结果显示,模型组的梗死指数为0.299±0.105,与假手术组比较P<0.01,说明造模成功;硝苯地平、复方丹参滴丸、参精胶囊低剂量组和参精胶囊高剂量组与模型组比较P<0.01,说明四种药物均对结扎大鼠左冠状动脉造成的急性心肌梗死有对抗作用;参精胶囊低、高剂量组与硝苯地平、复方丹参滴丸比较P<0.01,说明参精胶囊抗急性心肌缺血优于硝苯地平和复方丹参滴丸;参精胶囊高剂量组与参精胶囊低剂量组比较P<0.01,说明参精胶囊对抗急性心肌缺血时,高剂量、低剂量均有效,但高剂量优于低剂量。
实验例2:本发明胶囊剂对急性心肌缺血大鼠心肌保护作用的影响
1实验目的:观察本发明胶囊(参精胶囊)对缺血心肌的保护作用
2材料与方法
2.1材料
2.1.1动物,同实验例1
2.1.2药品与试剂,药品同实验例1。乳酸脱氢酶(LDH)试剂盒,批号:130141、肌酸激酶(CK)试剂盒,批号:040241,均由中生北控生物科技股份有限公司生产。
2.1.3仪器LISA-300PLUS全自动生化分析仪,法国HYCEL公司生产;离心机:Microfuge 25R型低温台式离心机,美国贝克曼公司生产。
2.2实验方法
动物分组及模型制备同实验一
造模24h后颈总动脉取血2ml,血凝固后离心取血清用于测定CK、LDH。
2.2.1血清CK、LDH含量测定,分别取大鼠血清20μl、10μl,按CK、LDH测定试剂盒说明书操作,测定血清CK、LDH含量。酶活性单位以U·ml-1血清表示。
2.3统计方法(同实验一)
3实验结果。
表2参精胶囊对急性心肌缺血大鼠血清CK、LDH含量的影响
注:与模型组相比*P<0.01与对照组相比##P<0.05
4数据分析
结果显示,模型组动物血清中CK、LDH含量显著高于假手术组,参精胶囊低、高剂量及硝苯地平、复方丹参滴丸均可明显降低CK、LDH水平。且参精胶囊低、高剂量组优于复方丹参滴丸和硝苯地平组。说明参精胶囊对缺血性心肌有保护作用。
实验例3:本发明胶囊剂对急性心肌缺血大鼠心电图的改善作用
1实验目的
观察本发明胶囊(参精胶囊)对急性心肌缺血大鼠心电图的改善作用
2材料与方法
2.1材料(动物、药品同实验一)
2.2实验方法(模型制备同实验一)
向大鼠四肢皮下插入针形电极,描记Ⅰ、Ⅱ、Ⅲ、aVF、aVL、aVR导联心电图。结扎后描记上述6导联心电图,24h后再次记录心电图,以观察心电图的改变。心电图ST-T的测量大鼠急性心肌缺血心电图多表现为T波高耸与R波融合,故以正向波的高点视为ST-T,以结扎后15min时的高点,与24h时正向波高点的差值为统计指标。
2.3统计方法(同实验例1)
3实验结果
表3参精胶囊对急性心肌缺血大鼠心电图ST-T的影响
注:与模型组相比*P<0.01与对照组相比▽P<0.05
4数据分析
结果显示参精胶囊可明显降低急性心肌缺血引起心电图ST-T抬高。与对照组比较有显著差异。说明该胶囊具有较好的抗急性心肌缺血作用。
Claims (8)
1.一种治疗心血管疾病的中药组合物,其特征在于,所述中药组合物包括以下重量份的原材料:
人参,6-12g;
黄精,10-30g;
川芎,9-15g;
郁金,9-15g;
β-环糊精,5-20g;
辅料,3-9g。
2.根据权利要求1所述的治疗心血管疾病的中药组合物,其特征在于,所述中药组合物包括以下重量份的原材料:
人参,6-9g;
黄精,10-18g;
川芎,9-12g;
郁金,9-12g;
β-环糊精,5-10g;
辅料,3-6g。
3.根据权利要求1所述的治疗心血管疾病的中药组合物,其特征在于,所述中药组合物包括以下重量份的原材料:
人参,6g;
黄精,15g;
川芎,12g;
郁金,12g;
β-环糊精,5g;
辅料,3g。
4.根据权利要求1所述的治疗心血管疾病的中药组合物,其特征在于,所述辅料包括可压性淀粉。
5.含权利要求1-4任一项所述的中药组合物的制剂,其特征在于,该制剂由中药组合物和药学上可接受的载体或赋形剂组成。
6.根据权利要求5所述的治疗心血管疾病的中药组合物,其特征在于,所述内用剂型为胶囊、颗粒剂、片剂或口服液剂。
7.一种制备权利要求1-4任一所述的治疗心血管疾病的中药组合物的方法,其特征在于,所述中药组合物胶囊的制备方法包括以下步骤:
1)取人参、黄精、川芎,将人参加入6倍量75%乙醇,回流提取3次,每次1.5小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;
2)郁金、川芎加14倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;
3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,调整相对密度,采用常规工艺,制成胶囊。
8.一种制备权利要求1-4任一所述的治疗心血管疾病的中药组合物的方法,其特征在于,所述中药组合物颗粒的制备方法包括以下步骤:
1)取人参、黄精、川芎将人参加入4倍量75%乙醇,回流提取3次,每次1小时,合并回流液,回收乙醇浓缩至波美度1.10-1.20;
2)黄精、川芎加10倍量水,用水蒸气蒸馏法提取挥发油,蒸馏6小时收集挥发油,再用β-环糊精包合得挥发油包合物;
3)过滤,滤液减压浓缩至波美度1.10-1.20,加入挥发油包合物和辅料,一步制粒,40℃-60℃低温干燥,制成颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910419371.6A CN110101817A (zh) | 2019-05-20 | 2019-05-20 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910419371.6A CN110101817A (zh) | 2019-05-20 | 2019-05-20 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110101817A true CN110101817A (zh) | 2019-08-09 |
Family
ID=67491211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910419371.6A Pending CN110101817A (zh) | 2019-05-20 | 2019-05-20 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110101817A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1682972A (zh) * | 2005-03-18 | 2005-10-19 | 北京师范大学 | 一种治疗心血管疾病的中药组合物及其制备方法 |
CN103372054A (zh) * | 2012-04-20 | 2013-10-30 | 北京因科瑞斯医药科技有限公司 | 一种治疗心脑血管疾病的药物及其制备方法 |
-
2019
- 2019-05-20 CN CN201910419371.6A patent/CN110101817A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1682972A (zh) * | 2005-03-18 | 2005-10-19 | 北京师范大学 | 一种治疗心血管疾病的中药组合物及其制备方法 |
CN103372054A (zh) * | 2012-04-20 | 2013-10-30 | 北京因科瑞斯医药科技有限公司 | 一种治疗心脑血管疾病的药物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101311160A (zh) | 一种丹参丹酚酸a的制备方法 | |
CN1931236B (zh) | 一种由丹参和红景天制成的药物组合物 | |
KR100529793B1 (ko) | 솔잎 추출물 및 이것의 용도 | |
CN102755474A (zh) | 一种治疗中风病的中药制剂及其制备方法 | |
CN110101817A (zh) | 一种治疗心血管疾病的中药组合物及其制备方法 | |
CN107050056A (zh) | 一种阿胶组合物及其制备方法与应用 | |
CN106727498A (zh) | 治疗心脑血管疾病的组合物及其制备与检验方法 | |
CN1291735C (zh) | 一种活血化瘀,行气止痛的中药滴丸制剂 | |
CN101879272A (zh) | 一种治疗冠心病的中药复方及其制备方法与应用 | |
CN1552415A (zh) | 一种治疗痴呆病的药物及其制备方法 | |
CN105833229A (zh) | 一种中药组合物在制备治疗心肌梗死的药物中的应用 | |
KR100964603B1 (ko) | 주목과 뽕나무 추출물을 이용한 당뇨 치료용 약학 조성물 및 이의 제조 방법 | |
CN101032534B (zh) | 救必应总皂苷的制备方法及应用 | |
CN1203886C (zh) | 一种治疗心血管疾病的药物及其制备方法 | |
CN1199979C (zh) | 一种治疗、预防心脑血管疾病的水溶性红花提取物及其口服制剂 | |
CN101181327B (zh) | 防治中风和胸痹的中药复方制剂及其制备方法 | |
CN1957967A (zh) | 太子参在制备治疗心血管疾病药物中的应用 | |
CN103720754A (zh) | 一种通脉多元微丸释药系统及其制备方法 | |
CN104587047B (zh) | 一种用于治疗心脑血管疾病的中药组合物 | |
CN101926845A (zh) | 一种药物组合物在制备治疗冠心病药物中的应用 | |
CN1233361C (zh) | 一种治疗心血管疾病的中药组合物 | |
CN103316217A (zh) | 一种治疗心脏病的中药制剂及其制备方法 | |
CN100502937C (zh) | 一种治疗心血管疾病的中药组合物及其制备方法 | |
CN102836320B (zh) | 治疗快速型心律失常的中药丸 | |
CN1482136A (zh) | 西洋参果总皂苷提取物及其提取、精制方法及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190809 |